Myomo (MYO) Q4 2025: Recurring Revenue Jumps 52% as O&P Channel Doubles, Margin Initiatives Gain Traction

2026-03-09 | By EarningsIQ Research

Myomo’s Q4 2025 marked a pivotal shift toward recurring revenue streams, with the O&P channel and MyoConnect program driving a 52% year-over-year increase in recurring sources and a doubling of O&P channel revenue. Strategic focus on payer contracts, cost reduction, and product innovation positions Myomo for improved operating leverage and lower cash burn in 2026, though Medicare Advantage headwinds and pipeline quality remain key watchpoints. Investors should monitor execution on channel expansion, payer adoption, and gross margin sustainability as Myomo scales its market presence.

Summary

• Recurring Revenue Expansion: Recurring patient sources now account for 42% of revenue, up sharply from last year.
• O&P Channel Momentum: Orthotics and prosthetics channel revenue doubled, confirming strategic channel shift traction.
• Margin and Cost Focus: Operating leverage and digital marketing overhaul aim to halve cash burn in 2026.

Performance Analysis

Q4 2025 delivered Myomo’s highest quarterly revenue for the year, though year-over-year comparisons show modest contraction due to a lower number of revenue units and slight ASP pressure. The sequential improvement was fueled by expanded penetration in the orthotics and prosthetics (O&P) channel, early MyoConnect referral program results, and strong international performance, particularly in Germany. The O&P channel posted an 81% year-over-year revenue increase for the quarter and doubled for the year, now comprising 9% of total revenue. International revenue hit a record $2.2 million, up 46% year-over-year and representing 19% of total sales, with Germany leading growth due to favorable reimbursement and expanded clinic partnerships.

Gross margin for the quarter reached 68.6%, a sequential improvement but down from the prior year due to higher warranty expenses and less overhead capitalization. Operating expenses rose 19% year-over-year, primarily from increased sales, clinical, and marketing investments, with advertising spend a notable driver. The operating loss widened to $2.8 million, and adjusted EBITDA swung negative, reflecting the cost of scaling new channels and R&D. Pipeline adds were slightly lower, impacted by seasonality and a company shutdown period, while the backlog remained robust at 199 patients. The company ended the year with $18.4 million in liquidity and plans to halve cash burn in 2026.

• Channel Mix Shift: Direct billing fell to 69% of revenue as recurring and O&P sources grew.
• Medicare Advantage Drag: Preauthorization denials and appeals slowed revenue conversion and increased pipeline dropouts.
• International Leverage: Germany’s statutory insurer coverage and O&P expansion drove outsized international growth.

Myomo’s Q4 performance demonstrates early success in its pivot to recurring channels, though execution risk remains as the payer and pipeline environment evolves.

Executive Commentary

Strategic Positioning

1. Recurring Revenue and Channel Diversification

Myomo’s business model is shifting from direct-to-patient sales toward recurring revenue via O&P channel and referral-driven MyoConnect program, which now accounts for 42% of revenue, up from 26% a year ago. The O&P channel delivered record revenue, and MyoConnect referrals comprised nearly 10% of pipeline adds, reflecting the company’s strategy to reduce customer acquisition costs and build a more predictable revenue base.

2. Insurance Market Access and Payer Contracts

A multi-state contract with Elevance Health, covering 45 million lives, marks a milestone in payer access, enabling faster patient authorization and revenue conversion. However, Medicare Advantage remains a challenge, with high preauthorization denial rates leading to appeals and pipeline attrition. Management is targeting expanded contracts and leveraging clinical evidence to drive further payer adoption.

3. Cost Structure Optimization and Margin Initiatives

Operating leverage is a central theme, with targeted reductions in material costs, outside services, and advertising spend, alongside investments in digital marketing and the launch of a mobile app to eliminate laptop costs per unit. These initiatives, along with scaling manufacturing, are expected to drive gross margin back to 70% and cut cash burn by half in 2026.

4. Innovation and Product Pipeline

Continued R&D investment underpins Myomo’s competitive edge, including the launch of MyoPro 2X, development of the next-gen MyoPro3, and a randomized control trial at the University of Utah to build payer-facing clinical evidence. Product enhancements are expected to improve patient outcomes and accelerate payer adoption.

5. International Expansion and Market Dynamics

International operations, led by Germany, are a growing contributor, with statutory insurer coverage and O&P partnerships reducing reimbursement friction. China remains on hold due to JV partner bankruptcy, but recapitalization efforts are underway to re-enter that market.

Key Considerations

Myomo’s Q4 represents a strategic inflection point, as the company leans into recurring sources and margin expansion while navigating payer and pipeline headwinds.

Key Considerations:

• Channel Resilience: O&P channel and MyoConnect are scaling but require continued investment in clinic training and referral relationships to sustain growth.
• Medicare Advantage Headwinds: High denial rates and appeals may continue to pressure pipeline conversion and drive patient dropouts.
• Gross Margin Sustainability: Margin expansion depends on successful cost reduction, manufacturing scale, and mobile app adoption to offset warranty and overhead costs.
• Payer Adoption: Success in securing multi-state and commercial contracts is critical for revenue acceleration and reducing cycle times.
• Pipeline Quality and Conversion: Lower pipeline adds and higher dropouts highlight the importance of referral quality and insurance prequalification.

Risks

Medicare Advantage remains a structural risk, with high preauthorization denials impacting both revenue timing and pipeline conversion. Direct billing’s flat outlook and potential volatility in advertising effectiveness could limit top-line acceleration. International growth is exposed to regulatory and JV partner risk, as seen in China. Margin expansion depends on successful execution of cost initiatives and channel mix management. Investors should monitor cash burn, payer dynamics, and pipeline quality as leading indicators of execution risk.

Forward Outlook

For Q1 2026, Myomo guided to:

• Revenue of $9 to $9.5 million, reflecting seasonal softness and higher operating expenses.
• Operating loss expected to be higher sequentially due to seasonal expense resets.

For full-year 2026, management guided to:

• Revenue of $43 million to $46 million, targeting approximately 10% growth.
• Gross margin improvement toward 70% as volume and cost initiatives scale.
• Operating expense growth limited to half the pace of revenue growth.
• Cash burn (free cash flow) to be reduced by roughly half versus 2025.

Management highlighted:

• Majority of revenue targeted from recurring sources by year-end.
• Continued investment in O&P and international channels, with direct billing expected to remain flat until marketing changes show clear impact.

Takeaways

Myomo’s Q4 2025 underscores a business model transition, with recurring revenue channels and payer partnerships driving a more scalable, margin-focused growth strategy.

• Recurring Channel Growth: O&P and MyoConnect are becoming core revenue drivers, reducing dependence on direct billing and advertising.
• Payer and Pipeline Execution: Expanded contracts and clinical evidence are critical to overcoming Medicare Advantage headwinds and improving pipeline conversion.
• Margin and Cash Flow Focus: Cost initiatives and digital transformation are expected to deliver higher gross margins and lower cash burn, but execution and market adoption remain pivotal watchpoints for investors.

Conclusion

Myomo’s Q4 2025 results validate its strategic pivot toward recurring revenue and channel diversification, with O&P and MyoConnect scaling meaningfully. Margin expansion and payer adoption are set to define 2026 performance, but pipeline quality and execution on cost initiatives will be the critical levers for sustainable growth and profitability.

Industry Read-Through

Myomo’s results highlight a broader medtech trend: shifting from direct-to-patient sales toward channel-driven, recurring revenue models that lower acquisition costs and improve scalability. Success in payer contracting and clinical evidence generation is increasingly vital for device adoption, especially as Medicare Advantage plans tighten preauthorization. International expansion remains attractive where reimbursement is less restrictive, but JV and regulatory risks persist. Other device companies should note the operational leverage from digital cost reduction and the importance of referral network development.

MYO Healthcare Medical Devices Recurring Revenue Orthotics Margin Expansion International Payer Contracts